Andrew Tsai
Stock Analyst at Jefferies
(3.05)
# 1,104
Out of 5,149 analysts
28
Total ratings
50%
Success rate
2.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AXSM Axsome Therapeutics | Maintains: Buy | $200 → $245 | $164.05 | +49.34% | 2 | Feb 3, 2026 | |
| DFTX Definium Therapeutics | Initiates: Buy | $30 | $17.69 | +69.59% | 1 | Jan 30, 2026 | |
| VTGN Vistagen Therapeutics | Downgrades: Hold | $15 → $0.9 | $0.61 | +47.54% | 3 | Dec 17, 2025 | |
| MRNA Moderna | Initiates: Hold | $30 | $49.83 | -39.80% | 1 | Dec 12, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $300 → $450 | $318.22 | +41.41% | 2 | Dec 9, 2025 | |
| MPLT MapLight Therapeutics | Initiates: Buy | $32 | $18.01 | +77.68% | 1 | Nov 21, 2025 | |
| ANRO Alto Neuroscience | Maintains: Buy | $15 → $25 | $20.11 | +24.32% | 2 | Nov 12, 2025 | |
| BIIB Biogen | Initiates: Buy | $190 | $184.02 | +3.25% | 1 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $40 → $35 | $15.87 | +120.54% | 3 | Jul 24, 2025 | |
| STOK Stoke Therapeutics | Initiates: Buy | $30 | $33.78 | -11.19% | 1 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $64.53 | +8.48% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $29 → $2.5 | $4.80 | -47.92% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $27 | $16.58 | +62.85% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $3.5 → $13 | $4.67 | +178.37% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $27.85 | +25.67% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $3 | $1.61 | +86.34% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $3.69 | +631.71% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $16 → $23 | $43.79 | -47.48% | 1 | Jun 1, 2020 |
Axsome Therapeutics
Feb 3, 2026
Maintains: Buy
Price Target: $200 → $245
Current: $164.05
Upside: +49.34%
Definium Therapeutics
Jan 30, 2026
Initiates: Buy
Price Target: $30
Current: $17.69
Upside: +69.59%
Vistagen Therapeutics
Dec 17, 2025
Downgrades: Hold
Price Target: $15 → $0.9
Current: $0.61
Upside: +47.54%
Moderna
Dec 12, 2025
Initiates: Hold
Price Target: $30
Current: $49.83
Upside: -39.80%
Praxis Precision Medicines
Dec 9, 2025
Maintains: Buy
Price Target: $300 → $450
Current: $318.22
Upside: +41.41%
MapLight Therapeutics
Nov 21, 2025
Initiates: Buy
Price Target: $32
Current: $18.01
Upside: +77.68%
Alto Neuroscience
Nov 12, 2025
Maintains: Buy
Price Target: $15 → $25
Current: $20.11
Upside: +24.32%
Biogen
Sep 25, 2025
Initiates: Buy
Price Target: $190
Current: $184.02
Upside: +3.25%
Sarepta Therapeutics
Jul 24, 2025
Maintains: Buy
Price Target: $40 → $35
Current: $15.87
Upside: +120.54%
Stoke Therapeutics
Jul 18, 2025
Initiates: Buy
Price Target: $30
Current: $33.78
Upside: -11.19%
Jul 14, 2025
Initiates: Buy
Price Target: $70
Current: $64.53
Upside: +8.48%
May 28, 2025
Downgrades: Hold
Price Target: $29 → $2.5
Current: $4.80
Upside: -47.92%
Mar 19, 2025
Maintains: Overweight
Price Target: $19 → $27
Current: $16.58
Upside: +62.85%
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5 → $13
Current: $4.67
Upside: +178.37%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $27.85
Upside: +25.67%
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $1.61
Upside: +86.34%
Sep 1, 2021
Initiates: Buy
Price Target: $27
Current: $3.69
Upside: +631.71%
Jun 1, 2020
Assumes: Buy
Price Target: $16 → $23
Current: $43.79
Upside: -47.48%